CARTITUDE-4: Nearly 75% of patients alive 3 years after cilta-cel treatment for myeloma
Nearly three years after treatment with the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel (cilta-cel), the risk of death was reduced by 45%
2025 EBMT Annual Meeting
Multiple Myeloma
News
Society Updates
SOHO Young Investigator Spotlight: Meet Andres Ramirez, MD
The SOHO Young Investigator Program (YIP) supports aspiring hematologic oncologists to attend the Annual Meeting in Houston and provides the opportunity to meet
Leukemia
News
Experts issue guidance on treating blood cancers during pregnancy
The incidence of hematologic malignancies presenting during pregnancy has increased, so Georgia Mills, MBBS (Hons), FRACP, FRCPA, of Northern Beaches Hospital in Sydney,
2025 EBMT Annual Meeting
Orca-T immunotherapy reduces GVHD over conventional allogeneic HSCT
Orca-T is an allogeneic stem cell and T-cell immunotherapy that leverages high-purity regulatory T cells to prevent GVHD.
Chronic Lymphocytic Leukemia
News
CHMP recommends pirtobrutinib for relapsed or refractory CLL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of pirtobrutinib for the
Aggressive B-Cell Lymphomas
Lymphoma
Is CAR-T feasible in elderly patients with B-cell lymphoma?
Octogenarians with B-cell lymphoma may be considered for chimeric antigen receptor (CAR) T-cell treatment, according to a study led by Mohamed A. Kharfan-Dabaja,
Lymphoma
Potential risk of lymphoma in individuals with large tattoos
Individuals with tattoos, particularly larger ones, may have an increased risk of lymphoma and skin cancer, according to a recent study. “We are
Leukemia
Lymphoma
Multiple Myeloma
News
Is it time to revisit MRD’s role in relapse detection?
A Viewpoints article published in The Lancet Haematology, calls for further research into the use of measurable residual disease (MRD) in hematologic malignancies.
Myeloproliferative Neoplasms
News
Polycythemia Vera
ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera
The Brazilian Health Regulatory Agency (ANVISA) has approved ropeginterferon alfa-2b (BESREMi) for the treatment of adult patients with polycythemia vera (PV).
News
Society Updates
SOHO launches new fundraising initiative
SOHO is launching a special fundraising initiative now through its Thirteenth Annual Meeting in Houston, Texas, taking place between September 3 and 6,
